Clinical trial
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute…
NCT00070174 · Children's Oncology Group, Other · Completed
Key facts
| NCT number | NCT00070174 |
|---|---|
| Title | Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy |
| Official title | Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study |
| Lead sponsor | Children's Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug, Procedure |
| Interventions | asparaginase, busulfan, cyclophosphamide, cyclosporine, cytarabine, daunorubicin hydrochloride, etoposide, gemtuzumab ozogamicin, methotrexate, mitoxantrone hydrochloride and 1 more |
| Enrollment | 350 |
| Start date | Dec 1, 2003 |
| Primary completion | Sep 1, 2006 |
| Completion | Dec 1, 2013 |
| First posted | Oct 7, 2003 |
| Last update posted | Feb 20, 2014 |
| Countries | Australia, Canada, Puerto Rico, Switzerland, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: